Rajesh Pradhan, MD
Cardiovascular Disease · Rapid City, SDNPI 1912115841
Payments from drug & device makers
What this record shows
15 manufacturers reported payments, led by Abbott at 58.5% of the total. 2025 is the largest year on record at $1,772, 3.7 times the $475 reported in 2019.
Across 48 payments — averaging $62.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Medtronic$360
- Boehringer Ingelheim$193
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$188
- Regeneron Healthcare Solutions, Inc.$143
- Pfizer$132
- plus $237 from 9 others
Across 227 payments — averaging $8081.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$440K
- Boehringer Ingelheim International GmbH$364K
- Boehringer Ingelheim Pharma GmbH & Co.kg$347K
- Eli Lilly$292K
- Amgen$172K
- Novartis$141K
- plus $77K from 4 others
What the payments were for
- Travel & lodging$1,45048%
- Food & beverage$1,57052%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 10 | $1,767 |
| Medtronic(2 entities) | 4 | $360 |
| Boehringer Ingelheim | 2 | $193 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $188 |
| Regeneron Healthcare Solutions, Inc. | 3 | $143 |
| Pfizer | 3 | $132 |
| Novartis | 5 | $76 |
| Amgen | 2 | $41 |
| Chiesi USA, Inc. | 2 | $26 |
| Actelion Pharmaceuticals US, Inc. | 2 | $24 |
| Boston Scientific | 1 | $19 |
| Johnson & Johnson | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRICLIP$1,531
- JARDIANCE$125
- IN.PACT AV$114
- IN.PACT Admiral$107
- EVKEEZA$106
- VYNDAQEL$101
How this compares
$3,020 in reported general payments places this provider in the 65th percentile of 33 cardiovascular disease providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 229 | $266,437 |
| CamzyosMavacamten | 27 | $222,342 |
| Repatha SureclickEvolocumab | 98 | $120,404 |
| XareltoRivaroxaban | 77 | $90,060 |
| Praluent PenAlirocumab | 40 | $51,198 |
| EntrestoSacubitril/Valsartan | 42 | $39,853 |
| JardianceEmpagliflozin | 38 | $22,388 |
| FarxigaDapagliflozin Propanediol | 13 | $13,538 |
| Repatha SyringeEvolocumab | 12 | $6,333 |
| Metoprolol Succinate | 422 | $5,685 |
| Atorvastatin Calcium | 499 | $4,957 |
| Potassium Chloride | 116 | $2,914 |
| Bumetanide | 55 | $2,143 |
| Losartan Potassium | 220 | $1,885 |
| Prasugrel Hcl | 15 | $1,781 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $132 | $266,437229 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $13 | $222,34227 claims |
| Johnson & JohnsonXarelto | $14 | $90,06077 claims |
| NovartisEntresto | $76 | $39,85342 claims |
| Boehringer IngelheimJardiance | $193 | $22,38838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 33 cardiovascular disease providers in South Dakota.
Other cardiovascular disease in Rapid City
- Bhaskar PurushottamRapid City$151K
- K HeilmanRapid City$5K
- Alexander SchabauerRapid City$4K
- Drew PurdyRapid City$2K
- Samuel DurrRapid City$2K
- Amid BitarRapid City$1K
- Stephen WasemillerRapid City$961
- Michael D'ursoRapid City$217
- Lewis FerrierRapid City$84
- Naveen RajpurohitSioux Falls$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.